Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Regulatory actions for Sept. 23, 2024
Regulatory snapshots: global drug submissions, approvals, clinical trial approvals, and other decisions involving Amplia, Apellis, Biocon, Biotech, Ipsen, Janssen, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Samsung Bioepis, Sanofi.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
FDA approves Sanofi's Sarclisa for use with Velcade, Bristol Myers' Revlimid, and dexamethasone in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
A new coalition of aid groups supporting Sudan will launch at this year's Clinton Global Initiative
15 nonprofits plan to invest in Sudan's humanitarian crisis, with The Bill & Melinda Gates Foundation leading a $2 million donation to mutual aid groups, aiming to raise $4.5 million more in two years. The Clinton Global Initiative's theme 'What’s Working' seeks effective solutions amid global issues. First lady Jill Biden to announce a new women’s health initiative. Sudan faces acute hunger and displacement, with local groups being the primary aid responders.
Sanofi Secures First-Line Nod for Sarclisa in Multiple Myeloma Treatment
FDA approved Sanofi’s Sarclisa for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, marking a significant advancement. Sarclisa, combined with VRd, reduces disease progression or death risk by 40%, offering a new treatment option. Sanofi aims to establish Sarclisa as a best-in-class therapy, with ongoing studies for broader applications.
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third
FDA approves Sanofi’s Sarclisa (siltuximab) with VRd as first-line treatment for NDMM patients not eligible for ASCT, reducing disease progression or death by 40% compared to VRd alone. This marks the third U.S. approval and first for newly diagnosed patients, based on IMROZ phase 3 study data.
OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical
ModeX Therapeutics, an OPKO Health company, appoints Dr. Giovanni Abbadessa as Chief Medical Officer to lead oncology development of multispecific antibodies. Dr. Abbadessa, with 20+ years of experience, previously served as VP at Sanofi, bringing expertise in early-stage oncology and clinical development.
Partner Spotlight: AQEMIA and Sanofi Harness Generative AI and Deep Physics to Power R&D
Integrating AI in drug discovery, especially with generative AI and deep physics, can accelerate molecule design and optimization. Sanofi and AQEMIA's collaboration exemplifies this, using physics-based calculations for data generation to enhance accuracy and speed.
40 doesn't look good on Hatch-Waxman
The Hatch-Waxman Act, despite increasing generic drug availability, has allowed pharmaceutical companies to maintain monopolies and high drug prices through extended patent periods, the Orange Book loophole, and FDA inaction. This has led to unaffordable medications for many Americans, contributing to health issues and increased medical costs. Reforms are needed to empower the FDA, increase transparency, eliminate conflicts of interest, rethink patent linkage, strengthen antitrust enforcement, and reform patent laws to prioritize public health over industry profits.
EMA committee recommends approval of Sanofi & Regeneron's Dupixent to treat ...
EMA's CHMP recommends Dupixent for EoE in children aged 1-11 years, supported by phase 3 EoE KIDS study showing histological remission and symptom improvement. Safety consistent with known profile. Pending EU approval.
Sarclisa approved in the US as the first anti-CD38 therapy in combination ...
Sarclisa approved by FDA as first anti-CD38 therapy in combination with VRd for newly diagnosed multiple myeloma patients not eligible for transplant, based on IMROZ phase 3 study showing significant PFS improvement.
© Copyright 2025. All Rights Reserved by MedPath